Clinical Trials Browser

Phase 1/2 × Neoplasm Metastasis × Bortezomib × Clear all

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1/2 Terminated

83 enrolled 31 charts

Neoplasm Metastasis